The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Loss of The Retinoblastoma Tumor-Suppressor Gene in Parathyroid Carcinoma
Open accessAbstract
BACKGROUND: The origin and molecular pathogenesis of parathyroid carcinoma are unknown. This life-threatening cause of primary hyperparathyroidism cannot be reliably distinguished from its benign counterpart on the basis of histopathological features alone. Because the PRAD1, or cyclin D1, gene, a cell-cycle regulator, has been implicated in a subgroup of benign parathyroid tumors, we examined the possibility that another cell-cycle regulator with possible functional links to PRAD1, the retinoblastoma tumor-suppressor gene (RB), might be involved in the molecular pathogenesis of parathyroid carcinoma. METHODS: Parathyroid carcinomas from 9 patients and adenomas from 21 were studied for evidence of tumor-specific loss of RB gene DNA (allelic loss) by analysis of four DNA polymorphisms and for evidence of altered expression oF RB protein by immunohistochemical staining. RESULTS: All of 11 specimens from 5 patients with parathyroid carcinoma and informative DNA patterns and 1 of 19 specimens from 19 patients with parathyroid adenoma and informative DNA patterns lacked an RB allele. Fourteen of 16 specimens (88 percent) from the nine patients with carcinoma had abnormal expression of RB protein (a complete or predominant absence of nuclear staining for the protein). None of the 19 adenomas, including the tumor with loss of an RB allele, had unequivocally abnormal staining for RB protein. CONCLUSIONS: Inactivation of the RB gene is common in parathyroid carcinoma and is likely to be an important contributor to its molecular pathogenesis. The presence of such inactivation may help to distinguish benign from malignant parathyroid disease and may have useful diagnostic, prognostic, and therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C.-M., & Livingston, D. M. (1989) · Cell · doi:10.1016/0092-8674(89)90507-2 · Cited by 897
Cited by
Autophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Somatic and Germ-Line Mutations of the HRPT2 Gene in Sporadic Parathyroid Carcinoma
Shattuck, T. M., Välimäki, S., Obara, T., Gaz, R. D., Clark, O. H., Shoback, D., Wierman, M. E., Tojo, K., Robbins, C. M., Carpten, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031237 · Cited by 599
Self-citationHyperparathyroid and Hypoparathyroid Disorders
Marx, S. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432508 · Cited by 481
Overview of the 2022 WHO Classification of Parathyroid Tumors
Erickson, L. A., Mete, O., Juhlin, C. C., Perren, A., & Gill, A. J. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09709-1 · Cited by 283
Metadata
- Authors
- Cryns, V. L., Thor, A., Xu, H.-J., Hu, S.-X., Wierman, M. E., Vickery, A. L., Benedict, W. F., & Arnold, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1994-03-17
- Volume
- 330
- Issue
- 11
- Pages
- 757-761
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2011834911
- Cited by
- 305
- References
- 1
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of The Retinoblastoma Tumor-Suppressor Gene in Parathyroid Carcinoma. https://app.cochat.ai/papers/10.1056/nejm199403173301105
- The paper
- Cryns, V. L., Thor, A., Xu, H.-J., Hu, S.-X., Wierman, M. E., Vickery, A. L., Benedict, W. F., & Arnold, A. (1994). Loss of The Retinoblastoma Tumor-Suppressor Gene in Parathyroid Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejm199403173301105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.